Navigation Links
Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
Date:11/6/2008

eadquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials,
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
2. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
3. Repligen Elects Earl Henry, M.D. to the Board of Directors
4. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
5. Repligen Announces Share Repurchase Program
6. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
7. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
8. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
9. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
10. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
11. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... a,new online resource for OTC drugs that have no negative side ... to know that non-toxic drugs are available today as,options to successfully ... are able to achieve relief without the adverse side effects,such as ... so many of us. , ...
... Stephen Joffe, Craig Joffe, and,Alan Buckey today filed an ... Exchange Commission. The group previously filed a 13D,disclosing ... LCAV ), which,operates 77 LasikPlus fixed-site laser vision correction ... Joffe is the founder and former Chairman and CEO ...
... did limit vomiting and results are preliminary, researchers ... Children who were given the steroid dexamethasone after ... they also faced an increased risk of bleeding ... early for safety reasons, a new study shows. ...
... inoperable disease, report says , , TUESDAY, Dec. 9 (HealthDay ... have improved overall survival of patients with advanced breast ... review of 128 clinical trials that included more than ... that use of anthracycline regimens led to a 22 ...
... deadliness of Alzheimer,s, report says , , TUESDAY, Dec. 9 ... fail to record severe dementia as a cause of death ... only points to a lack of knowledge about how dementia ... deadly illness, it suggests that deaths due to Alzheimer,s and ...
... for the Prom a Winner, Features Kelli Pedroia , ... Academy of Dermatology has announced that the Melanoma Foundation of New ... given for "significant contributions to the specialty of dermatology." The award ... in March of 2009. , , ...
Cached Medicine News:Health News:New Resource for No Side Effect Drugs 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 3Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 4Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 5Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 6Health News:Steroid After Tonsillectomy Raises Bleeding Risk 2Health News:Steroid After Tonsillectomy Raises Bleeding Risk 3Health News:Non-Hormonal Therapies Aid Breast Cancer Patients 2Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:Melanoma Foundation of New England Wins Gold Triangle Award From the American Academy of Dermatology 2
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced ... version of vigabatrin) for the treatment of cocaine and ... based upon, an in-depth review of the results obtained ... use of CPP-109 for the treatment of cocaine addiction ...
... Blue Belt Technologies, Inc., a Pittsburgh based medical device ... for use in orthopaedic and neurosurgery procedures, has closed ... of financing. The round was led by private ... Innovation Works (Pittsburgh) and consisted of both new investments ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 4Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 5Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 6Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3
Shandon Excelsior ES Tissue Processor continues the Thermo Electron Corporation tradition of offering one of the most advanced, traditional reagent instruments available today....
... the highly concentrated multi-purpose detergent formulated ... with an ultrasonic cleaner. MPD ... and organic material and safe enough ... clean surgical instruments manually or with ...
... grip the patients finger snugly. Wrap the patients ... Steel Finger Trap for an extra secure fit ... create a complete upper extremity traction system when ... Advanced Universal K Table. Stainless Steel Finger Traps ...
... Transmitters slot into ... TeleMon companion monitor, so ... at the patient's side. ... interrupting transmission and storage ...
Medicine Products: